Monograph: Inflammatory Bowel Disease: Diagnosis and Treatment for Improved Patient Outcomes
This JAAPA supplement monograph outlines the course of IBD, pharmacologic options available, and strategies to improve therapy according to disease characteristics in individual patients. Also available, Clinical Dialogue, eCase Challenge 1, and eCase Challenge 2: Inflammatory Bowel Disease: Diagnosis and Treatment for Improved Patient Outcomes.

Monograph: Inflammatory Bowel Disease: Diagnosis and Treatment for Improved Patient Outcomes

Lawrence Herman, MPA, PA-C, DFAAPA; Richard H. Davis Jr, PA-C; Robert K. Bobilin, MS, MPAS, PA-C

Inflammatory bowel disease (IBD) is a chronic condition that results from dysregulated activity of the immune system. Patients most often present with abdominal pain and diarrhea. The distinction between UC and CD is largely based on distribution of the affected sites and morphologic changes of the involved bowel. As with many other diseases, patients with IBD are apt to be first seen in primary care, then managed with a team approach that incorporates continuous involvement of the primary care provider. It is therefore critical that primary care clinicians be knowledgeable about the differential diagnosis of IBD, the various treatment options available, and strategies for tailoring therapy according to disease characteristics in individual patients. 

Primary care providers can play a key role by working in concert with gastroenterologists to manage IBD, treating comorbidities, initiating preventative health interventions and providing patients with support and guidance. Consequently, it is incumbent on primary care clinicians to understand the course of IBD, the efficacy and safety of current therapeutic strategies, the risk of complications from the disease itself or its treatment, and the importance of preventative health measures. Regarding the latter concern, primary care clinicians can ensure that patients are up to date with respect to recommended immunizations as well as screenings for bone health and skin and colorectal cancer. Moreover, these clinicians often monitor patients’ response to IBD treatments and adverse effects of therapy, results of laboratory studies, and adherence to prescribed regimens.

Through this broad range of roles, the primary care clinician can help optimize the management of IBD so patients can achieve the best possible outcomes and experience an improved quality of life.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:

  • Recognize patients with IBD presenting in the primary care setting, differentiate them from patients with other disorders, and appropriately stratify the level of disease.
  • Outline the pharmacologic options available for patients with IBD, whether UC or CD, and outline the most appropriate treatments for patients depending on their disease state.
  • Discuss appropriate tools and evidence-based guidelines to assist in evaluating, initiating, and managing patients with IBD.
  • Describe proposed strategies to improve the clinician-patient relationship for individuals with IBD.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.50 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until January 31, 2019.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Professor and Dean Emeritus (Retired)
College of Health Sciences
PA Studies
Gardner-Webb University
Consultant: Novo Nordisk
Speaker's Bureau: Novo Nordisk

Richard H. Davis Jr, PA-C
Senior PA
Division of Gastroenterology, Hepatology, and Nutrition
University of Florida College of Medicine
Gainesville, FL
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Robert K. Bobilin, MS, MPAS, PA-C
Assistant Professor (Retired 2016)
Director of Student Evaluations
School of PA Studies
University of Florida
Gainesville, FL
 

UF Health Family Medicine
Kernan Square Clinic
Jacksonville, FL
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel and Joanne Jeffers, Medical Logix, LLC and Nancy Baxter, Baxter Medical Communications, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace and Jennifer Williams have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

Biologics, mesalamine, thiopurines

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by independent educational grants from AbbVie, Salix Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
967 Registered Users